Indevus jointly granted the rights along with Rottapharm Madaus Group, an Italian pharmaceutical group, as required by a prior agreement between Indevus and Rottapharm Madaus. Indevus and Rottapharm Madaus will share equally in the proceeds from the license transaction.
Under the terms of the agreement, Allergan will pay up to $9 million to each of Indevus and Rottapharm Madaus, including a $7 million up-front license fee and up to $2 million in sales threshold milestone payments. Allergan will be responsible for all regulatory and marketing activities in Canada.
Sanctura XR is indicated for the once-daily treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
Glenn Cooper, chairman and CEO of Indevus, said: “This agreement further consolidates the rights for Sanctura XR within one highly competent organization. We continue to pursue opportunities to obtain marketing partners in Japan, Korea and China, where we agreed to jointly license rights with Rottapharm Madaus.”